← Back to directory
AB
Ally Bridge Group
New York, NYWebsite ↗
Ally Bridge Group is a global healthcare investment management firm focused on high-impact life science innovation, investing across private and public markets. The firm aims to generate superior risk-adjusted returns by combining scientific and clinical research with M&A and capital markets expertise.
Last raised
Unknown
Latest fund size
—
Ally Bridge Group Innovation Capital Partners III
AUM
$1.4B
estimated
Funds raised
Capital this firm has raised, newest first
Ally Bridge Group Innovation Capital Partners III
Unknown
—
Recent investments
Companies this firm has funded, newest first
| Company | Round | Amount | Date | Source |
|---|---|---|---|---|
| AdvanCellLead | Growth | $315M | Jul 2026 | |
| Climb Bio, Inc. | — | — | May 2026 | |
| CalyxoLead | Growth | $40M | Apr 2026 | |
| Imperative Care | Growth | — | Mar 2026 | |
| Precision IO Group Inc.Lead | — | — | Feb 2026 | |
| ProMIS Neurosciences | — | — | Jan 2026 | |
| ProfoundBioLead | Series B | $112M | Feb 2024 | |
| Elligo Health Research | Growth | $135M | Sep 2021 |
Sources
Where this data came from